Title | FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Posada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain RK, Heiden MGVander |
Journal | Nat Cancer |
Volume | 2 |
Issue | 4 |
Pagination | 414-428 |
Date Published | 2021 Apr |
ISSN | 2662-1347 |
Keywords | Brain Neoplasms, Breast Neoplasms, Fatty Acid Synthases, Fatty Acids, Female, Humans, Tumor Microenvironment |
Abstract | Brain metastases are refractory to therapies that control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore metabolic adaptations required for brain metastatic breast cancer growth may introduce liabilities that can be exploited for therapy. Here, we assessed how metabolism differs between breast tumors in brain versus extracranial sites and found that fatty acid synthesis is elevated in breast tumors growing in brain. We determine that this phenotype is an adaptation to decreased lipid availability in brain relative to other tissues, resulting in a site-specific dependency on fatty acid synthesis for breast tumors growing at this site. Genetic or pharmacological inhibition of fatty acid synthase (FASN) reduces HER2+ breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies. |
DOI | 10.1038/s43018-021-00183-y |
Alternate Journal | Nat Cancer |
PubMed ID | 34179825 |
PubMed Central ID | PMC8223728 |
Grant List | S10 OD018072 / OD / NIH HHS / United States R01 CA168653 / CA / NCI NIH HHS / United States R01 CA259253 / CA / NCI NIH HHS / United States P30 CA014051 / CA / NCI NIH HHS / United States S10 OD023524 / OD / NIH HHS / United States R35 CA197588 / CA / NCI NIH HHS / United States R01 CA208205 / CA / NCI NIH HHS / United States T32 GM007287 / GM / NIGMS NIH HHS / United States R01 NS118929 / NS / NINDS NIH HHS / United States R01 CA201276 / CA / NCI NIH HHS / United States R35 CA242379 / CA / NCI NIH HHS / United States R35 CA197743 / CA / NCI NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States |
Related Faculty:
Neal Lindeman, M.D.